Britain and America have concluded a important bilateral deal that will guarantee no duties on UK drug products entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to boost expenditure on medicines through the public health system. This pledge secures that duties on these crucial products will remain at zero for a timeframe of 36 months.
This agreement comes after previous warnings to hike tariffs on branded pharmaceutical products, with potential rates mentioned up to 100%.
"This agreement between the UK reinforces the international landscape for new treatments and brings much-needed balance to American-British drug exports," a statement said.
Trade Impact
Drugs constitute one of the the United Kingdom's biggest exports to the America, which is by far the largest market for large UK drugmakers.
Trade data indicate that in the 12 months leading up to last September, the UK shipped medicines valued at billions to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This agreement secures work, stimulates investment and facilitates the UK to establish itself as a worldwide center for life sciences," a minister stated.
Specific UK Commitments
The pact involves several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to raise overall NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Last year, rebates were more than 20%.
Recent Tensions
This agreement takes place against a long-running tension between the sector and the ministers over spending levels and regulatory access.
The disagreement were heightened by claims that American consumers were charged several times more for the equivalent treatments than people in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
